GU Cancers 2023 | Ongoing clinical trials in bladder cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on ongoing clinical trials in bladder cancer, including randomized trials investigating sacituzumab govitecan versus a taxane, as well as enfortumab vedotin plus pembrolizumab in the front-line setting. Erdafitinib, an FGFR3 inhibitor, is currently being assessed in combination with checkpoint inhibitors. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.